Clinical Trial Update: Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease [Phase 4]

View source ↗

Summary

This open-label Phase 4 safety extension study of natalizumab in Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Crohn's Disease | Phase 4 | Status: COMPLETED